Par Pharmaceutical Companies has entered into pharma partners agreements with two well know big pharma companies, Watson Pharmaceuticals and Actavis Group, respectively,to purchase for cash five generic products that are currently marketed in the U.S. .
These generic drugs are marketed by Watson or Actavis, while eight Abbreviated New Drug Applications currently awaiting regulatory approval and a generic product in late-stage development.
The closing of the pharma partners purchase agreements is contingent upon the closing of Watson's acquisition of Actavis.
The five currently marketed products include morphine sulfate extended release capsules, the generic version of Kadian, fentanyl transdermal system CII, the generic equivalent of Duragesic, nifedipine extended release tablets, the generic version of Adalat , diltiazem hydrochloride extended release capsules, the generic equivalent of Cardizem CD, and metoclopramide hydrochloride tablets, the generic version of Reglan.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Actavis (formerly Watson Pharmaceuticals)
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity